What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors
About this episode
Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Get every episode summarized
Each time Hematologic Oncology Update publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Hematologic Oncology Update
CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal S...
Hematologic Oncology Update
Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Pre...
Hematologic Oncology Update
Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH...
Hematologic Oncology Update
Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH...
Hematologic Oncology Update